Lanvis (Tioguanine)

Tioguanine is metabolized inside cells to thioguanine nucleotides, which become incorporated into DNA and RNA, disrupting purine synthesis. This leads to faulty nucleic acid function and cytotoxicity, especially in rapidly dividing cells like leukemic blasts.

The dose of Lanvis is individualized by the prescribing physician based on the patient’s age, weight, disease type, and laboratory parameters. Clinicians calculate the appropriate amount and schedule, and adjustments are made according to therapeutic response and tolerance.

Safety of tioguanine in pregnancy and lactation has not been definitively established. It is generally considered contraindicated or used only when the potential benefit outweighs the risk. Women who are pregnant, planning pregnancy, or breastfeeding should discuss alternatives with their healthcare provider.

To order Lanvis, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Lanvis (tioguanine) is one of several thiopurine agents, alongside mercaptopurine and azathioprine. Compared with mercaptopurine, tioguanine has a higher intracellular conversion to active nucleotides, which may result in different efficacy or toxicity profiles. Choice of agent depends on disease, patient tolerance and physician preference.

Lanvis should be stored at ambient temperature, below 25 °C, in its original container. Keep the product away from moisture, direct sunlight and excessive heat. Ensure the packaging remains sealed until use to maintain stability.

Lanvis is taken orally, usually as a tablet swallowed whole with water. It may be administered with or without food, according to the prescribing clinician’s instructions. Patients should follow the dosing schedule provided and not alter the regimen without medical advice.

The most serious risks include severe bone‑marrow suppression leading to neutropenia or anemia, hepatic veno‑occlusive disease, and increased susceptibility to infections. Rare but life‑threatening reactions such as hypersensitivity, pancreatitis, or secondary malignancies may also occur, requiring immediate medical attention.

Lanvis is contraindicated in individuals with known hypersensitivity to tioguanine or other thiopurines. Patients with severe hepatic impairment, uncontrolled infections, or pre‑existing severe bone‑marrow failure should avoid the drug. Use is also discouraged in pregnant or nursing women unless clearly justified by a physician.